Foghorn Therapeutics Inc. Common Stock (FHTX)

Price$3.98

Value ScoreD

Growth ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-22.68%

Price vs S&P 500 (4W)-15.06%

VGM Score42.92

Market Capitalization$251.30M

All Metrics

Book Value / Share (Quarterly)$0.00

P/TBV (Annual)1643.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.14%

Cash Flow / Share (Quarterly)$-1.49

Price vs S&P 500 (YTD)-31.67%

Net Profit Margin (TTM)-266.88%

EPS (TTM)$-1.17

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-1.17

Revenue Growth (5Y)135.14%

EPS (Annual)$-1.18

ROI (Annual)-108880.00%

Net Profit Margin (5Y Avg)-1830.74%

Cash / Share (Quarterly)$3.13

Revenue Growth QoQ (YoY)-45.11%

ROA (Last FY)-37.50%

Revenue Growth TTM (YoY)20.08%

EBITD / Share (TTM)$-1.27

Operating Margin (TTM)-301.34%

Cash Flow / Share (Annual)$-1.52

P/B Ratio2512.96x

P/B Ratio (Quarterly)2666.96x

Net Income / Employee (Annual)$-700,800

EV / Revenue (TTM)5.80x

Net Interest Coverage (TTM)-52.05x

ROA (TTM)-35.39%

EPS Incl Extra (Annual)$-1.18

Current Ratio (Annual)2.73x

Quick Ratio (Quarterly)2.87x

3-Month Avg Trading Volume0.15M

52-Week Price Return-0.93%

Revenue / Employee (TTM)$266,300

Tangible BV / Share (Quarterly)$-1.36

P/S Ratio (Annual)8.13x

Asset Turnover (Annual)0.16x

52-Week High$6.95

Operating Margin (5Y Avg)-1876.78%

EPS Excl Extra (Annual)$-1.18

CapEx CAGR (5Y)-68.53%

26-Week Price Return-6.75%

Quick Ratio (Annual)2.68x

13-Week Price Return-25.69%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.92x

Enterprise Value$163.63M

Revenue / Share Growth (5Y)111.13%

Asset Turnover (TTM)0.13x

Revenue / Employee (Annual)$291,600

Pretax Margin (Annual)-240.33%

Cash / Share (Annual)$2.80

3-Month Return Std Dev65.38%

Net Income / Employee (TTM)$-710,600

ROE (Last FY)-108880.00%

Net Interest Coverage (Annual)-51.77x

EPS Basic Excl Extra (Annual)$-1.18

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.17

Receivables Turnover (Annual)0.13x

ROI (TTM)-301.61%

P/S Ratio (TTM)8.90x

Pretax Margin (5Y Avg)-1828.27%

Revenue / Share (Annual)$0.49

Tangible BV / Share (Annual)$0.00

Price vs S&P 500 (52W)-29.13%

Year-to-Date Return-20.74%

5-Day Price Return1.42%

EPS Normalized (Annual)$-1.18

ROA (5Y Avg)-29.76%

Net Profit Margin (Annual)-240.33%

Month-to-Date Return-9.89%

Cash Flow / Share (TTM)$-2.38

EBITD / Share (Annual)$-1.32

Operating Margin (Annual)-279.49%

LT Debt / Equity (Annual)0.00x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.17

P/B Ratio (Annual)2666.96x

Pretax Margin (TTM)-266.88%

Book Value / Share (Annual)$0.00

Price vs S&P 500 (13W)-35.44%

Beta2.87x

P/FCF (Annual)1.31x

Revenue / Share (TTM)$0.41

ROE (TTM)-301.61%

52-Week Low$3.27

vGradeD

gGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.29est. -0.31

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.38

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
FHTXFoghorn Therapeutics Inc. Common Stock	D	B	D	$3.98
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Foghorn Therapeutics discovers and develops medicines targeting dependencies in the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company is advancing two lead candidates—FHD-286, a selective ATPase inhibitor, and FHD-609, a protein degrader—for the treatment of hematologic cancers and solid tumors.